Premium
Onychomycosis in children: Safety and efficacy of antifungal agents
Author(s) -
Gupta Aditya K.,
Mays Rachel R.,
Versteeg Sarah G.,
Shear Neil H.,
Friedlander Sheila F.
Publication year - 2018
Publication title -
pediatric dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.542
H-Index - 73
eISSN - 1525-1470
pISSN - 0736-8046
DOI - 10.1111/pde.13561
Subject(s) - medicine , adverse effect , dosing , antifungal , cochrane library , randomized controlled trial , incidence (geometry) , intensive care medicine , clinical trial , pediatrics , dermatology , surgery , physics , optics
Onychomycosis is an uncommon condition in childhood, but prevalence in children is increasing worldwide.The objective was to review the efficacy and safety of systemic and topical antifungal agents to treat onychomycosis in children. Databases (Pubmed, OVID , Scopus, clinicaltrials.gov, Cochrane Library) were searched. Seven studies were selected for inclusion. Only one was a randomized controlled trial. In total, 208 children were administered antifungal agents for the treatment of onychomycosis. Four reports of mild adverse events were documented (1.9% of treated children), one of which discontinued treatment (0.5%). Limitations of this review are the lack of randomized controlled trials available in pediatric onychomycosis. These findings suggest that antifungal therapies used to treat onychomycosis in children are associated with a low incidence of adverse events. Current dosing regimens for antifungal drugs are effective and appear safe to use in children, notwithstanding that the Food and Drug Administration has not approved any of these agents for the treatment of onychomycosis in children. To our knowledge, this review is the most up‐to‐date, comprehensive summary of pediatric onychomycosis treatment.